Background: Intrauterine growth restriction (IUGR) is defined as fetal growth less than the normal growth potential of a specific infant because of genetic or environmental factors. Fetal growth restriction or intrauterine growth restriction is one of the leading causes of perinatal mortality and morbidity in newborns. Fetal growth restriction is a complex multifactorial condition resulting from several fetal and maternal disorders. Objective of present study was to find out incidence of IUGR and assessment and evaluation of different important changes in IUGR.Methods: Women who attended the Obstetric OPD in their 1st trimester of pregnancy and those who were thought would be able to visit the antenatal clinic for their fortnightly check-up regularly were screened for intrauterine foetal growth retardation. Women with irregular and uncertain menstrual history and where the 1st trimester USG foetal crown rump length did not corroborate with the menstrual gestational age were excluded from this study.Results: Incidence of IUGR was 18.2% and 84% were found to be asymmetrical. IUGR was found to be double among primigravids and women above 30 years. It had been observed that IUGR was associated with certain conditions like short stature (52%), pregnancy induced hypertension (24%) and anaemia (12%).Conclusions: Thus, early USG screening along with robust screening for maternal BMI, nutritional status, and anaemia can assist the obstetric team in providing early diagnosis, prompt intervention, and better outcome in pregnancy with fetal growth restriction.

Background: Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorder affecting five to ten percent women of reproductive age group. Variability of signs and symptoms along with metabolic syndrome as one of the long term complications make it worthy of early diagnosis and treatment. Medical management of PCOS is aimed at the treatment of metabolic derangements, anovulation, hirsutism, and menstrual irregularities.Methods: 140 patients, using inclusion and exclusion criteria, were selected and randomly divided into two groups (seventy in each) and age, BMI, waist hip ratio, blood pressure (systolic, diastolic), serum fasting insulin, fasting blood sugar, total cholesterol, HDL, LDL, triglycerides were measured. Study group were given {Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg)} (MI+DCI) twice daily and the control group were given Myo-inositol (1 gm) (MI) twice daily for six months. Same variables were measured at the end of three and six months and compared with repeated measurement ANOVA using SPSS (version 20).Results: Comparison between these two groups before study was non-contributory. Combined drug therapy has provided statistically significant decrease in BMI, W:H ratio, Diastolic BP, Fasting blood sugar at the end of both 3rd and 6th month but in case of LDL it was at the end of 3 months. Combined drug therapy also increased the HDL level significantly in both the occasions.Conclusions: Combined medical therapy by (MI+DCI) is very much helpful in reducing the metabolic complications of PCOS without any major side effects.